CD4+ CAR-T细胞耗竭与BCMA CAR-T治疗后多发性骨髓瘤早期复发相关
多发性骨髓瘤患者接受靶向B细胞成熟抗原(BCMA)的CAR-T治疗后多数仍会复发。研究发现持续缓解者CAR-T细胞持久性更高且CD8+效应记忆T细胞比例显著更高,而短期缓解者细胞毒性CD4+ CAR-T细胞频率增加,这些细胞在输注后早期体内扩增但表达耗竭标志物HAVCR2和TIGIT并保持多克隆性;非经典单核细胞在骨髓瘤微环境中富集并可能通过转化生长因子β等机制诱导CAR-T细胞功能障碍。
要点
- 持续缓解者CAR-T细胞持久性高于短期缓解者,CD8+效应记忆T细胞比例显著更高。
- 短期缓解者细胞毒性CD4+ CAR-T细胞频率增加,表达耗竭标志物HAVCR2和TIGIT。
- 非经典单核细胞在骨髓瘤微环境中富集,可能通过转化生长因子β诱导CAR-T细胞功能障碍。
核心结论
- 细胞毒性CD4+ CAR-T细胞耗竭与BCMA CAR-T治疗后多发性骨髓瘤早期复发相关,非经典单核细胞可能通过转化生长因子β等机制诱导CAR-T细胞功能障碍。
研究设计与样本
- 研究纳入接受BCMA CAR-T细胞治疗的多发性骨髓瘤患者,比较持续缓解与短期缓解患者的T细胞特征及骨髓瘤微环境。
主要发现
- 持续缓解者CAR-T细胞持久性高于短期缓解者,且CD8+效应记忆T细胞比例显著更高。
- 短期缓解者细胞毒性CD4+ CAR-T细胞频率增加,这些细胞输注后早期体内扩增但表达耗竭标志物HAVCR2和TIGIT并保持多克隆性。
- 非经典单核细胞在骨髓瘤微环境中富集,可能通过包括转化生长因子β在内的机制诱导CAR-T细胞功能障碍。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma is characterized by frequent clinical relapses after conventional therapy. Recently, chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen (BCMA) has been established as a treatment option for patients with relapsed or refractory disease. However, although >70% of patients initially respond to this treatment, clinical relapse and disease progression occur in most cases. Recent studies showed persistent expression of BCMA at the time of relapse, indicating that immune-intrinsic mechanisms may contribute to this resistance. Although there were no preexisting T-cell features associated with clinical outcomes, we found that patients with a durable response to CAR T-cell treatment had greater persistence of their CAR T cells than patients with transient clinical responses. They also possessed a significantly higher proportion of CD8+ T-effector memory cells. In contrast, patients with short-lived responses to treatment have increased frequencies of cytotoxic CD4+ CAR T cells. These cells expand in vivo early after infusion but express exhaustion markers (hepatitis A virus cellular receptor 2 [HAVCR2] and T-cell immunoglobulin and mucin domain-containing-3 [TIGIT]) and remain polyclonal. Finally, we demonstrate that nonclassical monocytes are enriched in the myeloma niche and may induce CAR T-cell dysfunction through mechanisms that include transforming growth factor β. These findings shed new light on the role of cytotoxic CD4+ T cells in disease progression after CAR T-cell therapy.
引用
- Ledergor G, Fan Z, Wu K, et al. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2024. PMID: 38574299. doi:10.1182/bloodadvances.2023012416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。